Navigation Links
PTC Therapeutics to Present at Upcoming Investor Conferences
Date:8/29/2013

SOUTH PLAINFIELD, N.J., Aug. 29, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will participate in following conferences in September:

  • Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics, will participate in a panel at the Citi 8th Annual Biotech Conference in Boston on Wednesday, September 4 at 10:00 a.m. ET. The panel is titled Born to Run: RNA Therapies Racing to the Market.
  • Shane Kovacs, Chief Financial Officer of PTC Therapeutics, will present a company overview at the Morgan Stanley Global Healthcare Conference in New York City on Wednesday, September 11, 2013 at 11:10 am ET.
  • Shane Kovacs, Chief Financial Officer of PTC Therapeutics, will present a company overview at Stifel Healthcare Conference in Boston on Thursday, September 12, 2013 at 9:10 am ET.

The presentations will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com. The presentation will be archived for 2 weeks following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

About PTC Therapeutics, Inc.
PTC is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. While PTC's discovery progra
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
2. Carolus Therapeutics and The Alpha-1 Project Collaborate to Validate CT-2009 Target as Important in Human Disease
3. Echo Therapeutics Announces Management Changes
4. aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology
5. aTyr Pharma Expands Executive Leadership Team to Support Development of New Therapeutics Based on Physiocrine Biology
6. Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech
7. PTC Therapeutics Reports Second Quarter 2013 Financial and Corporate Results
8. Aratana Therapeutics Reports Second Quarter 2013 Financial Results
9. Breckenridge Enters Into Agreement to Acquire Certain Cypress Assets from Pernix Therapeutics
10. Northwest Biotherapeutics Announces Registered Direct Offering
11. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015 Eli Lilly and Company (NYSE: ... 7 to update the investment community and media on ... conjunction with the 75th American Diabetes Association® Scientific Sessions, ... business, including a review of the Phase III data ... the ADA meeting. The meeting will be ...
(Date:3/30/2015)... ISELIN, N.J. , March 30, 2015 /PRNewswire/ ... a medical device company focused on non-invasive continuous ... it has achieved its wireless mobile communication milestone, ... sensor to transmit data to any mobile platform. ... the strategic transformation of the Company,s technology from ...
(Date:3/30/2015)... , March 30, 2015  BioDelivery Sciences ... the primary efficacy endpoint in the Phase 3 ... placebo for the treatment of painful diabetic neuropathy ... endpoints showed statistically significant improvement over placebo.  In ... was observed.  The results of this trial provide ...
Breaking Medicine Technology:Lilly Announces Date for Diabetes Investor Meeting 2Echo Therapeutics, Inc. Achieves Wireless Mobile Communication Milestone 2Echo Therapeutics, Inc. Achieves Wireless Mobile Communication Milestone 3BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 2BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 3BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 4BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 5
... Colo., March 29, 2011 Encision Inc. (Pink Sheets: ... laparoscopic safety have become intensive topics of discussion in ... Surgery Magazine (March 2011).  The potential complications from laparoscopic ... probably prompted by a recent California case.  The issue ...
... 29, 2011 BioDrain Medical, Inc. (OTC Bulletin ... FDA cleared Streamway™ System for automated surgical fluid ... installation of its patented Streamway™ System in a ... several procedures utilizing the Streamway System and the ...
Cached Medicine Technology:Stray Energy Burns Become a "Hot Topic" in Recent Publications 2Stray Energy Burns Become a "Hot Topic" in Recent Publications 3BioDrain Medical, Inc. Completes Installation of Its Streamway™ Automated Surgical Fluid Disposal System in Minnesota Hospital 2BioDrain Medical, Inc. Completes Installation of Its Streamway™ Automated Surgical Fluid Disposal System in Minnesota Hospital 3
(Date:3/30/2015)... This report studies the global ... forecast period of 2014 to 2019. This market ... 6.5% from 2014 to 2019. , Further Inquiry ... the global pharmacovigilance and drug safety software market ... basis of functionality, namely, adverse event reporting software, ...
(Date:3/30/2015)... Dr. Shahdad Arami is ... will receive $200 off their Invisalign treatment. Many people ... wearing a mouthful of metal. Invisalign offers an alternative. ... braces is effective for straightening teeth but has no ... their oral appearance. The Invisalign system allows both teenagers ...
(Date:3/30/2015)... Angeles, CA (PRWEB) March 30, 2015 ... traditional blue polo for yellow to inspire courage in ... suffers from Severe Combined Immunodeficiency (SCID). SCID causes affected ... bone marrow transplant is needed to allow the development ... second transplant last Friday, created a video with his ...
(Date:3/30/2015)... V/NO (Virtually No Alcohol) Wines have a ... opening/closing and for reuse. Consumers simply twist the cup, turn ... Yorkers, professionals, and basically anyone can now enjoy a ... back socially or pair with meals at work, home, or ... wine and that means Napa Wine grapes undergo the ...
(Date:3/30/2015)... TX (PRWEB) March 30, 2015 ... been Drummond Certified™ in the second AS4 test ... Inc., the trusted leader in interoperability software testing. ... Oracle and Software AG participated in this vendor-neutral ... represents the first AS4 interoperability certifications for IBM, ...
Breaking Medicine News(10 mins):Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4Health News:Northridge Cosmetic Dentist, Dr. Arami, is Now Offering a New Promotion on Invisalign 2Health News:24Hr HomeCare Staff Hosts #WearYellowForSeth Campaign for Five-Year-Old Boy with Severe Combined Immunodeficiency 2Health News:Napa Valley Alcohol-Removed Red, White & Rosé Wines Have Launched. 2Health News:Latest AS4 Standard-Based Products Drummond Certified™ 2Health News:Latest AS4 Standard-Based Products Drummond Certified™ 3
... Reporter , THURSDAY, June 2 (HealthDay News) -- New ... part of the plan, don,t appear to harm the ... clear low-carb is effective for weight loss," said study ... exercise physiology at the Johns Hopkins University School of ...
... liver diseases such as hepatitis C (HCV) are typically ... disease progression. For patients who question whether less invasive ... consider. Elastography and serum markers are two such diagnostic ... issue of Hepatology , a journal of the ...
... HealthDay Reporter , THURSDAY, June 2 (HealthDay ... more likely to suffer from anxiety, loneliness, low self-esteem ... and math test scores, new research suggests. Children ... during the potentially disruptive period before their parents divorce, ...
... study from North Carolina State University shows that talking about ... transgender community. The finding may help efforts to promote safer ... and also sheds light on broader questions related to safer ... is the fact that we,re seeing evidence of devastatingly high ...
... 2, 2011 In a multicenter clinical trial, ... higher doses of stereotactic radiation therapy requiring fewer ... low-to-intermediate-risk prostate cancer. Results of the trial, ... , showed that stereotactic body radiation therapy (SBRT), ...
... of the most lethal cancers, advanced melanoma, has improved response ... immunotherapy drug Interleukin-2, according to research led by scientists from ... University Health Goshen Center for Cancer Care. The ... of Medicine , mark the first vaccine study in the ...
Cached Medicine News:Health News:Low-Carb, High-Fat Diets May Not Pose Risk to Arteries 2Health News:Low-Carb, High-Fat Diets May Not Pose Risk to Arteries 3Health News:Noninvasive diagnostics may offer alternative to liver biopsy for assessing liver fibrosis 2Health News:Divorce Can Hurt Kids' Math Scores, Friendships 2Health News:Divorce Can Hurt Kids' Math Scores, Friendships 3Health News:Safer sex: Study examines sexual communication in transgender community 2Health News:Higher doses of radiation in fewer treatments proved safe, effective for low-risk prostate cancer 2Health News:Therapeutic melanoma vaccine improves response rate, progression-free survival 2Health News:Therapeutic melanoma vaccine improves response rate, progression-free survival 3
... HmX offers three-dimensional VCS ... specificity and efficiency in ... reticulocyte analysis. With its ... dependability, HmX is an ...
... utilize the infinity-corrected optical system ... in cell checking. The CKX31 ... suited to routine applications in ... culture and embryology to immunology ...
The BX41 offers an outstanding range of features and optical performance for the clinical market. With an emphasis on high-quality optics and a rigid frame, the BX41 offers improved versatility and e...
Advanced ergonomic design allows greater comfort even after long hours of use. The focus knob and stage handle are located equidistant from the operator, permitting one-handed operation in a natural ...
Medicine Products: